JAK2 and asthenia: Literature comparison analysis shows that these newly identified AEs have been clearly reported in similar JAK2/FLT3 inhibitors: phase III trial data of fedratinib indicates that 27% of patients experienced constipation and 24% asthenia (32); in ruxolitinib treatment, 5.5% of patients had constipation, 3.2% had decreased appetite, and 15.4% presented with asthenia (33).